1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTP or DOTMP) is the phosphonate analog of DOTA. Its radioactive holmium-166 complex localizes in the skeleton and can deliver high dose radiation to the bone and bone marrow while the thulium complex is used as hyperfine in vivo NMR shift reagent to separate intracellular and extracellular sodium resonances.
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTP or DOTMP) is the phosphonate analog of DOTA. It is synthesized in a Mannich type reaction by reacting cyclen tetrahydrochloride with phosphorous acid and formaldehyde. It forms complexes with lanthahide ions, which have high thermodynamic stability. Its thulium complex, TmDOTP is used as hyperfine in vivo NMR shift reagent to separate intracellular and extracellular sodium resonances. The beta emitting holmium-166 complex of DOTP is a promising radiopharmaceutical for the treatment of multiple myeloma and for the ablation of bone marrow. The holmium complex localizes in the skeleton and can deliver high dose radiation to the bone and bone marrow. Another bone seeking radiopharmaceutical, the alpha emitting bismuth-212 complex of DOTP, targets bone tissue in general, and especially sites where increased bone formation occurs. The Bi-212-DOTP complex can target and irradiate micro metastases in newly formed bone matrix.